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analytical methods including sampling procedures are described. The GFR should therefore be interpreted with some reservation because of its relatively more inconsistency than the blood samples. Further, it might have the notation eGFR for estimated, because it is this formula, which is listed in the text. One of the conclusions in this study thus is that the authors recommend more meta-analyses on the prevention of renal failure through food protein restriction.
Another discordance between studies is their observation time and thus the nephropathy stages in the patient groups. This is compensated for by statistical analyses by sensitivity analyses and removing of subgroup comparison. Throughout the study the statistics seem to compensate for inhomogeneity, missing data etc. This makes it difficult to follow the actual number of cases in each class. However, that is what can be done in pooling of data for meta analyses.
All in all, it is a clinically important study, which is very well carried out. In spite of limitations with the application of GFR (eGFR) it may be the appropriate approach for measurement of renal failure. No doubt the study will contribute to further understanding of development in methods to prohibit or retard renal failure in patients with diabetes. This study should be published
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THE STUDY
It is meaningless to continue comparing low protein diet with normal protein diet on kidney marker GFR as measured by serum creatinine. It is significant to compare the endpoint as kidney deathdialysis or transplantation GENERAL COMMENTS Dr. Uru Nezu et al demonstrate low protein diet was significantly associated with improvement of kidney function in diabetic nephropathy by a meta-analysis. There are some concerns:
1. Table 1: there were three studies (meloni, 2004, zeller, 1991 and ciavarella, 1987) which characteristics of GFR>=100ml/min/1.73m2.
As we all known, Glomerular hyperfiltration was a candidate marker for diabetic nephropathy. Therefore, it shouldn't oversimplify to think that all increased GFR mean kidney function improvement. The
Author should carry out subgroup analyses and further discuss the result. Moreover, GFR from serum Cr only is not an accurate marker of renal function, more accurately, it should be compared the difference of endpoint (such as renal death-dialysis or transplantation) between LPD and normal protein diet. 
VERSION 1 -AUTHOR RESPONSE
Review 1:MAURO GIORDANO, Associate Internal Medicine Second University of Naples Comment: The authors made an interesting meta-analysis on the effects of LPD on renal function in diabetes mellitus. They concluded that using a cut-off value for protein intake < 0.9 g/kg/day (APIR < 0.9) the LPD showed a protective effect on diabetic nephropathy by improving GFR and proteinuria, without worsening either glicemic control or nutritional status. This meta-analysis is a well designed study, which gives us an important conclusion on the usefulness of LPD in the management of diabetic nephropathy.
Reply from authors: Thank you for reviewing our meta-analysis. I hope this paper will enlighten the clinical attitude of many physicians in charge of diabetes care.
Reviewer2: Lone G.M. Jørgensen, specialist in clinical biochemistry, senior consultant, University Hospital Copenhagen No competing interests Comment 1: The aim of this work is very interesting and a clinically important issue. Diabetic nephropathy is responsible for critical and life threatening disease in diabetes, type 1 as well as type 2. The study is very well carried out. The search strategy is appropriate; the statistics are based on recommended methods, and the various discordances between studies are documented in supplementary tables. The outcome parameters in this clinical study are categorized into primary and secondary outcome measures. All of them are biochemical tests. As primary outcome measure the glomerular filtration rate (GFR) is selected, while secondary outcome measures were proteinurea and two blood sample tests: The HaemoglobinA1c (HbA1c) and the serum albumin. Of those the two blood samples are the most consistent, however not assumed the direct measure and test for nephropathy and renal failure. Taken over time especially the GFR has been measured in very different ways with different methods. This is also the case in the included studies, where the analytical methods including sampling procedures are described. The GFR should therefore be interpreted with some reservation because of its relatively more inconsistency than the blood samples. Further, it might have the notation eGFR for estimated, because it is this formula, which is listed in the text. One of the conclusions in this study thus is that the authors recommend more meta-analyses on the prevention of renal failure through food protein restriction.
Reply from authors: I am appreciated your comments. I totally agree that GFR, our primary outcome, was measured in different method according to each studies. Some of the studies even applied eGFR by estimation formula as you pointed out. These measurement variation would cause a risk of measurement instability or inconsistency. I previously discussed about this issue in Strength and limitation of the study as following: "Although the directions of the intervention were consistent across the most studies, the CIs were in small overlap and also the heterogeneity was not negligible. This inconsistency may be partly explained by difference in study protocol.". I revised the text to the following: " This inconsistency may be partly explained by difference in study protocol. GFR was measured in different ways in the RCTs included in this meta-analysis as is also the case in the clinical practice."
Comment 2: Another discordance between studies is their observation time and thus the nephropathy stages in the patient groups. This is compensated for by statistical analyses by sensitivity analyses and removing of subgroup comparison. Throughout the study the statistics seem to compensate for inhomogeneity, missing data etc. This makes it difficult to follow the actual number of cases in each class. However, that is what can be done in pooling of data for meta analyses. All in all, it is a clinically important study, which is very well carried out. In spite of limitations with the application of GFR (eGFR) it may be the appropriate approach for measurement of renal failure. No doubt the study will contribute to further understanding of development in methods to prohibit or retard renal failure in patients with diabetes. This study should be published
Reply from authors: Thank you for your valuable comments. We tried to minimize the heterogeneity across the studies by conducting several subgroup and sensitivity analyses. In terms of nephropathy stage, the initial subgroup analysis was not effective to uncover the effect of LPD among patients who are actually suffered from nephropathy. Thus, the following sensitivity analysis was conducted to remove the normal stage patients together with microalbuminuria. We believe that this was the maximum extent we could do in available data.
Reviewer: Hui Min Jin, MD, Division of Nephrology, Shanghai Pudong Hospital, Shanghai, China There is no competing interests Comment 1: It is meaningless to continue comparing low protein diet with normal protein diet on kidney marker GFR as measured by serum creatinine. It is significant to compare the endpoint as kidney death-dialysis or transplantation
Reply from authors: Thank you for pointing out the important limitation regarding our primary endpoint. It is true that GFR is no more than a surrogate marker of more ADL-related or lifethreatening event such as dialysis, kidney transplantation or death. Although we did not object and try to pool these outcome data in this meta-analysis, we strongly feel the needs of that evidence. Thus I revised the text in Strength and limitations of the study to the following: "In addition, long-term clinical validity of GFR is not sufficient. We hope that more large-scale prospective studies or another metaanalysis will elucidate the effect of LPD on the change in GFR as well as more long-term clinical outcome such as mortality, dialysis or transplantation.".
Dr. Uru Nezu et al demonstrate low protein diet was significantly associated with improvement of kidney function in diabetic nephropathy by a meta-analysis. There are some concerns:
1. Table 1 : there were three studies (meloni, 2004, zeller, 1991 and ciavarella, 1987) which characteristics of GFR>=100ml/min/1.73m2. As we all known, Glomerular hyperfiltration was a candidate marker for diabetic nephropathy. Therefore, it shouldn't oversimplify to think that all increased GFR mean kidney function improvement. The Author should carry out subgroup analyses and further discuss the result. Moreover, GFR from serum Cr only is not an accurate marker of renal function, more accurately, it should be compared the difference of endpoint (such as renal deathdialysis or transplantation) between LPD and normal protein diet.
Reply from authors: Considering the glomerular hyperfiltration theory, I totally agree that increasing GFR may not always represent improvement of kidney function. It was true that the baseline GFR of the three studies that you listed above (meloni, 2004, zeller, 1991 and ciavarella, 1987) were high. We assume that this was result by their clinical characteristics, although might partly be affected by the variations in the measurement method. I believe that the subgroup analysis excluding these studies would not bring the answer to the question whether increasing GFR really contribute the better prognosis or not, irrespective of the results. The evidence we need is the long-term clinical validity of improving GFR and this is only be answered by large-scale prospective study that measured both pre-post GFR and more critical clinical outcome such as dialysis or mortality. We don't have those data in this meta-analysis. Thus I revised the text in Strength and limitations of the study to the following: "In addition, long-term clinical validity of GFR is not sufficient. We hope that more large-scale prospective studies or another meta-analysis will elucidate the effect of LPD on the change in GFR as well as more long-term clinical outcome such as mortality, dialysis or transplantation.".
Fig B:
Because different measurements of protein excretion were reported in the included trials. The Author also should carry out subgroup analyses based on a variety of measurements of protein excretion.
Reply from authors: Thank you for the comment (The effect of LPD on protein excretion is described in fig.3 not in supplementary fig.B ). We conducted a subgroup analysis according to measurement index of proteinuria and added these data into table 3. Prior to do this, we had to integrate the digit number within each measurement index of proteinuria. Thus we revised the text in data exctraction section to the following: "Different digit number of proteinuria (mg/24h) and albuminuria (g/24h) were converted to fit the above scales.". As the result, we got the four subgroups as we added in the revised version of table 3: proteinuria (g/24h), albuminuria (mg/24h), albuminuria (μg/min),and albumin/creatinine ratio (mg/mmol). Although the interepretation is difficult, the p-value showed the significant difference between the subgroups (p<0.00001) and only albuminuria (μg/min) was diminished by LPD. Albumin/creatinine ratio (mg/mmol) seemed to favor control diet, however, the result was from only one study using this measurement index.
3. Figure C showed no effect of low protein diet on serum albumin. Was the result associated with poor limited protein intake? This intake in the LPD group was higher than the Recommended Dietary Allowance. The Author should further discuss the result.
Reply from authors: Thank for pointing out the possible effect of the actual protein restriction level on serum albumin. This is always an important factor in this kind of dietary interventional trial. We excluded a study of poor diet compliance (APIR 1.02) and conducted sensitivity analysis. As the result, serum albumin between the intervention group was not significantly differed p=0.22, I2=91%) and we revised and added the following text in subgroup and sensitivity analyses: "As for serum albumin, the sensitivity analysis excluding only one study by Dussol et al which showed poor diet compliance (APIR 1.02) showed no significant change after LPD (-0.25, 95% CI -0.64 to 0.15, p=0.22, I2=91%, data not shown in table).". As further decreasing the pooled size of the meta-analysis, we should be careful not to be conclusive regarding this issue. Thus we added the following text in second paragraph in Strength and limitations of the study: "In addition, APIR was also utilized in the sensitivity analysis of serum albumin, in which three studies with fair diet compliance consistently showed no worsening of nutritional status. Since the number of the included studies were limited, the interpretation should be careful. We need another large scale of RCT for more accurate conclusion in terms of this issue on malnutrition.".
4. There were 3 earlier Meta analyses on this topic. Compared to the Pan's Meta analysis, there were two studies Koya, et al 2009 and velaques et al 2008 added in present studies. Firtst, in Koya, et al study, the level of 24h UUN in LPD group was 1.0, which was no significantly deference with the control group. Velaques et al study had so short (4 month) follow-up time that it may not be sufficient to capture differences in GFR. Based on the situation above, we need more large-scale randomly control studies to understand whether LPD is effective in renoprotection rather than more Meta analysis to provide the confused results for clinicians.
Reply from authors: I agree with your comments regarding the limitations of the newly added two RCTs. As you point out, Koya's RCT could not achieve sufficient patients' diet compliance. In addition, the intervention period in Velaques's RCT might be too short to detect the GFR change. Although I have only limited knowledge regarding this topic by myself, it is discussed by Zeller et al in 1991 that the serum creatinine needs at least 4 months to reach steady state. Recently this is quoted by Robertson et al in their meta-analysis. Thus we added the following text in the last part of Comparison with other studies: " As another difference between our study and Pan's meta-analysis is that we added two newly conducted RCTs by Koya, et al15 and Veláquez et al31. However, the level of 24h UUN was 1.0 in the study by Koya, et al, which was no less than that in the control group (APIR=1.0). In addition, the intervention period of the study by veláquez et al was only 4 months, which might be insufficient to detect the change in GFR as discussed by Zeller et al40.We need more large-scale RCT of sufficient long and sufficient compliance for more conclusive evidence regarding the effect of LPD on GFR.
